Leo Pharma disappoints as deficit surpasses USD 720m

Leo Pharma’s deficit increased fivefold in 2021 to a bottom line result of DKK 4.9bn (USD 726.6m). Acting CEO Anders Kronborg acknowledges that this looks very disappointing, but says that the company has a plan to turn things around as early as next year.


Revenues are down as the bottom line deficit at Leo Pharma grows, the company’s annual report for 2021 reveals.

The company’s negative result has increased fivefold, from a reported DKK -951m in 2020 to DKK -4.9bn in 2021 (USD 141m to USD 726.6m), whereas the top line shrinks after a number of product divestments to DKK 9.96bn from preceding period’s DKK 10.13bn (USD 1.47bn from USD 1.5bn).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs